Guenter R. Janhofer
Chief Scientific OfficerDr. Guenter R. Janhofer, M.D., Ph.D. is Chief Scientific Officer of IRulya Therapeutics Inc. (formerly known as Quince Therapeutics, Inc.) from October 2023. He has been Head of Development and Chief Medical Officer of BTG Limited since joining in March 2009 and since 2011 respectively. Dr. Janhofer has more than 25 years of experience in the pharmaceutical industry across all phases of clinical development from Phase I to end-stage life-cycle management and across a wide variety of therapeutic areas, including cardiovascular, metabolic, neuroscience, infectious diseases, respiratory, osteoporosis and oncology. Having started as Medical Director of Desitin Pharmaceuticals in Hamburg, Germany, he later served Merck & Co., Inc. in functions of growing complexity and scope, both at the subsidiary and at the headquarters’ level. He served as Vice President of Global Medical and Scientific Affairs and has been instrumental of bringing Internet technology to Merck’s clinical development process. Dr. Janhofer holds an MD degree from Hamburg University, PhDs in Climatology and Medicine from the University of Bochum and a post-doc degree (Habilitation) from the University of Technology in Berlin, where he is a faculty member at the School of Public Health.
Positions
- Company NameIRulya Therapeutics Inc.Stock CodeIRLAPositionChief Scientific OfficerColleagues
- BRBrigette RobertsCEO, Principal Executive Officer & Director
- JCJohn C. MilitelloCFO, Principal Financial Officer & Principal Accounting Officer
- KRKeith R. FandrickChief Operating Officer
- PBPaul B. YuChairman of Scientific Advisory Board
- LDLeone D. PattersonDirector
- JPJames P. ValentineDirector
- MBMark BrodyMember of Clinical Advisory Board
